Prevalence of Microsatellite Instability High (MSI-H) or DNA Mismatch Repair Deficiencies (dMMR) in Selected Advanced Solid Tumors in China, Japan, Korea, Singapore and Taiwan

Multi-centered, retrospective, observational study to evaluate the prevalence of MSI-H/dMMR in selected advanced solid tumors in Asia - Multi-centered, retrospective, observational study to evaluate the prevalence of MSI-H/dMMR in selected advanced solid tumors in Asia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040387

Enrollment

1600

Registered

2020-05-15

Start date

2020-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: <Japanese cohort> 1. Patients must be over 20 years of age at diagnosis 2. Histologically or cytologically-documented, advanced solid tumor of one of the following types: endometrial, ovarian, cervical, biliary tract, pancreas and gastric cancer (including gastroesophageal junction). 3. Patients must have had a tumor tissue sample collected at the time of their advanced stage diagnosis for MSI-H testing that is no older than 3 years. 4. Patients must have MSI status tested by MSI Test Kit (FALCO). 5. Must have medical history documented within 3 months prior the pathology diagnosis. 6. Progressed or relapsed after standard of care treatment 7. Informed consent form (ICF) requirements or other requirements set forth by the local ethics committee have been met for patient.

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

Measure	Time frame
MSI-H/dMMR prevalence in selected advanced solid tumor types	—

Secondary

Measure	Time frame
1. Demographic and clinicopathological characteristics of MSI-H/dMMR patients 2. Treatment patterns for all patients in this study	—

Countries

Japan,Asia(except Japan)

Contacts

Public ContactReiko Endo

Parexel International GLOBAL MONITORING OPERATIONS

Reiko.endo@parexel.com03-5543-9517

Outcome results